Literature DB >> 22119184

Type of health insurance and the substance abuse treatment gap.

Ellen Englert Bouchery1, Henrick J Harwood, Joan Dilonardo, Rita Vandivort-Warren.   

Abstract

OBJECTIVE: Most individuals reporting symptoms consistent with substance use disorders do not receive care. This study examines the correlation between type of insurance coverage and receipt of substance abuse treatment, controlling for other observable factors that may influence treatment receipt.
METHOD: Descriptive and multivariate analyses are conducted using pooled observations from the 2002-2007 editions of the National Survey on Drug Use and Health. The likelihood of treatment entry is estimated by type of insurance coverage controlling for personal characteristics and characteristics of the individual's substance use disorder.
RESULTS: Multivariate analyses that control for type of substance and severity of disorder (dependence vs. abuse) find that those with Civilian Health and Medical Program of the Uniformed Services/Veterans Affairs, Medicaid only, Medicare only, and Medicare and Medicaid (dual eligibles) have 50% to almost 90% greater odds of receiving treatment relative to those with private insurance.
CONCLUSIONS: The privately insured population has substantially lower treatment entry rates than those with publicly provided insurance. Additional research is warranted to understand the source of the differences across insurance types so that improvements can be achieved.
Copyright © 2012 Elsevier Inc. All rights reserved.

Mesh:

Year:  2011        PMID: 22119184     DOI: 10.1016/j.jsat.2011.09.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  9 in total

1.  State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.

Authors:  Hefei Wen; Janet R Cummings; Jason M Hockenberry; Laura M Gaydos; Benjamin G Druss
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

2.  Unmet need for treatment for substance use disorders across race and ethnicity.

Authors:  Norah Mulvaney-Day; Darcie DeAngelo; Chih-Nan Chen; Benjamin L Cook; Margarita Alegría
Journal:  Drug Alcohol Depend       Date:  2012-06-02       Impact factor: 4.492

3.  Healthcare coverage and service access for low-income adults with substance use disorders.

Authors:  Mark Olfson; Christine Mauro; Melanie M Wall; C Jean Choi; Colleen L Barry; Ramin Mojtabai
Journal:  J Subst Abuse Treat       Date:  2021-12-29

4.  Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis.

Authors:  Hannah K Knudsen; Michelle R Lofwall; Sharon L Walsh; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2019-05-01

5.  Health insurance coverage and the receipt of specialty treatment for substance use disorders among U.S. adults.

Authors:  Janet R Cummings; Hefei Wen; Alexis Ritvo; Benjamin G Druss
Journal:  Psychiatr Serv       Date:  2014-08-01       Impact factor: 3.084

6.  The impact of race, income, drug abuse and dependence on health insurance coverage among US adults.

Authors:  Nianyang Wang; Xin Xie
Journal:  Eur J Health Econ       Date:  2016-05-04

7.  Effects of accountable care and payment reform on substance use disorder treatment: evidence from the initial 3 years of the alternative quality contract.

Authors:  Elizabeth A Stuart; Colleen L Barry; Julie M Donohue; Shelly F Greenfield; Kenneth Duckworth; Zirui Song; Robert Mechanic; Elena M Kouri; Cyrus Ebnesajjad; Michael E Chernew; Haiden A Huskamp
Journal:  Addiction       Date:  2016-09-24       Impact factor: 6.526

8.  Support for Alcohol Policies in Marginalized Populations.

Authors:  Pamela J Trangenstein; Nina Mulia; Camillia K Lui; Katherine J Karriker-Jaffe; Thomas K Greenfield; Rhonda Jones-Webb
Journal:  Alcohol Alcohol       Date:  2021-06-29       Impact factor: 2.826

9.  Treatment for illegal drug use disorders: the role of comorbid mood and anxiety disorders.

Authors:  Maria Melchior; Elena Prokofyeva; Nadia Younès; Pamela J Surkan; Silvia S Martins
Journal:  BMC Psychiatry       Date:  2014-03-26       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.